Clinical trial NCT03448874: Seal-G MIST (Minimally Invasive Sealant/Spray Technology) System Safety Study [SEALAR Study]
Official title: Seal-G MIST System Safety Study [SEALAR Study]
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Colorectal Cancer
Diverticulitis Colon
Lead sponsor: Sealantis Ltd.
Sponsor class: INDUSTRY
First posted: 2018-02-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Controlled, Randomized, single blind study
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate safety of Seal-G MIST System in reinforcing colorectal anastomosis, in subjects undergoing colorectal surgery.

Detailed description: Study procedures:

Pre-surgery:

* Screening will be performed among adult subjects who are scheduled for an elective colorectal surgery. Once potential eligibility to the study is determined based on the study's inclusion/exclusion criteria, study procedures will be explained to the candidate and participation will be offered.
* Informed consent process.
* Pre-surgery assessments will be according to the routine practice at the site and determined by the treating physician.

Intra-operative:

* During the surgery, after confirmation of the intra-operative exclusion criteria, completion of anastomosis creation and only after leak test was performed , subjects will be allocated to one of the two treatment arms with a 1:1 ratio based on a randomization scheme (either to the Standard of care (SOC) or to Seal-G MIST arms).
* Device (Seal-G MIST System) application (to Seal-G MIST treatment arm only).

Post-operative follow-up:

* Subjects will be followed during post-operative period until discharge from the hospital for clinical and subclinical leaks according to the SOC.
* In an event of suspected anastomotic leak, patient will be treated according to severity of leak and PI clinical judgement (conservative treatment, drainage, diversion, anastomosis take down).
* Subjects will be followed up for leaks and related AE/SAEs at the day of the surgery and for a period of 15 weeks (±2 weeks) post-surgery, including the following activities:

  * Daily while hospitalized (in accordance with the site routine procedures)
  * At 1 month (±1 week) and 15 weeks (±2 weeks) post-surgery (Hospitalization for elective procedure (i.e. chemotherapy treatments) will not be considered as SAEs)

Eligibility criteria: Inclusion Criteria:

1. Subject \>18 years
2. Subject is scheduled for elective open or laparoscopic colorectal resection (including left colectomy, sigmoidectomy, anterior resection, subtotal colectomy) surgery (including robotic) involving the creation of circular stapler anastomosis
3. Subject signs and dates a written Informed Consent Form, indicates an understanding of the study procedures and follow-up requirements and is willing to comply with them

Exclusion Criteria:

1. Anastomosis is expected to be ≤ 10cm from anal verge
2. Surgery involves stoma creation
3. Subject who underwent a prior pelvic radiation therapy
4. Subject with a BMI \> 40 or \<19
5. Subject with American Society of Anesthesiologists (ASA) status higher than 3
6. Albumin level \< 3 gr/dl
7. Hemoglobin level \< 8 g/dl on day of surgery
8. Subject has a diagnosis of bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, and carcinomatosis
9. Subject treated with immunosuppressive agents within 28 days prior to study enrollment (including corticosteroids)
10. Serious or uncontrolled co-existent diseases (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction within 6 months from surgery, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection, uncontrolled diabetes mellitus with episodes of hospitalization due to hypo or hyperglycemia within 6 months of surgery)
11. Subject known to have distant metastases, such as liver, lung, bone etc. metastases (not including local and regional lymph nodes)
12. Subject with known sensitivity to Indigo carmine dye (E132)
13. Subject who according to the investigator clinical judgement is not suitable for participation in the study
14. Subject with a life expectancy of less than 1 year
15. Subject requires more than one anastomosis during the surgery
16. Subject is scheduled for another surgery during the follow up period of this study
17. Subject participating in any other study involving an investigational (unapproved) drug or device
18. Woman who is known to be pregnant or breast-feeding or woman who is planning pregnancy or breast-feeding in the 5 next months
19. Vulnerable subjects (e.g. mentally handicapped, prisoners, etc.)

Primary outcomes:
measure: Incidence of overall subject pre-specified* procedure related Adverse Events
timeFrame: up to 15 weeks (±2 weeks) post-surgery
Secondary outcomes:
measure: Incidence of clinical anastomotic leaks
timeFrame: up to 15 weeks (±2 weeks) post-surgery
measure: Incidence of subclinical/ radiological leaks
timeFrame: up to 15 weeks (±2 weeks) post-surgery
measure: Incidence of Serious Adverse Events (SAE) complications
timeFrame: up to 15 weeks (±2 weeks) post-surgery
measure: Incidence of collection/abscess without demonstrated leak
timeFrame: up to 15 weeks (±2 weeks) post-surgery
measure: Incidence of reoperation
timeFrame: up to 30 days post-surgery
measure: Incidence of postoperative mortality
timeFrame: up to 15 weeks (±2 weeks)
measure: Hospital length of stay
timeFrame: From date of surgery until the time for "Ready to be discharged" (in days), an average of 10±4 days
measure: Incidence of "deployment failure"
timeFrame: during surgery
Other outcomes:
Locations:
Study officials:
affiliation: Chief Medical Officer
name: Moshe Kamar, MD
role: STUDY_DIRECTOR
References: